While “Some Things Come with Age,” others do not. That’s the new slogan from the Ad Council and the Alzheimer's Association (AA) to try and boost awareness of the me...

Advanced temperature-controlled container specialist, Tower Cold Chain has continued the expansion of its global team with the appointment of a Regional Commercial M...

With winnings from its arbitration battle against Johnson & Johnson in hand—alongside a jump in its own product sales—Alkermes seems to be feeling itself heading...

More than 2.4 million people in the United States use warfarin to keep their blood from clotting after a heart attack, stroke or other serious thromboembolic co...

What is the key to success in the competitive migraine market? An analysis by Veeva Systems suggests medical science liaison (MSL) engagement with key opinion leader...

With a European approval for chronic kidney disease nod in hand, Boeringer Ingelheim and Eli Lilly's Jardiance is looking to catch up to AstraZeneca's Farx...

Lupin is no stranger to FDA rebukes, though its latest write-up from the U.S. drug regulator certainly could have been worse for the company. Following an inspect...

As a shortage of key chemotherapy drugs continues to upend cancer treatment across the country, the FDA has resorted to securing some of the meds from China. Afte...

Merck is bringing more heat in its battle against drug price negotiation provisions in the Inflation Reduction Act (IRA), filing Tuesday in federal court in Washingt...

Five weeks after getting no response from the U.S. Department of Health and Human Services on his request for more information on the potential financial impact of E...